Pfizer/BioNTech request full FDA approval of COVID-19 booster vaccine

Pfizer/BioNTech have initiated an application for full FDA approval of its COVID-19 vaccine booster shot for individuals aged 16 and up, the companies announced Wednesday, noting plans to complete the application later this week.

The request for the so-called supplemental biologics license application draws on Phase 3 clinical trial data among 306 participants aged 18 to 55 who received a third dose between 4.8-8 months following the initial two-dose series, with some 2.6 months of follow-up. The companies said levels of neutralizing antibodies were 3.3 times higher following the third dose, versus the second dose.

Side effects within a week after the booster were mild-to-moderate, the companies said, with most frequent side effects including “injection site pain, fatigue, headache, muscle and joint pain, and chills,” similar to the second dose of the primary series.- READ MORE

Related Articles

(PREMIUM) PAINE IN THE MORNING: What you need to know this Wednesday – January 11, 2023

Here’s what you need to know today, Wednesday – January 11, 2023. This Censorious Pfizer Board Member Was A Major Influence On Lockdowns – The latest of the Twitter Files is reported by Alex Berenson, who was granted access to messaging systems from the times before Elon Musk took over. His first round of reporting concerns…

To access this post, you must purchase The Hot Wire, The Hot Wire (DG), Monthly Supporter​ or Monthly Supporter​ (DG).

(PREMIUM) PAINE IN THE MORNING: 13 things you need to know this Tuesday – January 4, 2022

  There is also an ad free audio version of this episode you can listen to HERE. Schools Across The Country See Last-Minute Closures Due To COVID-19 Staffing Issues – On Sunday evening, schools across the United States abruptly announced closures. The phenomenon occurs as the Omicron variant spreads throughout the United States, inducing staffing…

To access this post, you must purchase The Hot Wire, The Hot Wire (DG), Monthly Supporter​ or Monthly Supporter​ (DG).

Responses